BridgeMD
New treatment option for Cytomegalovirus Infections
Official title Quantiferon CMV to Identify Treatment Need for Asymptomatic CMV Infection After Solid Organ Transplant (QUANTIFOT)
ClinicalTrials.gov ID: NCT06341543
What this study is testing
- What it's testing
- Context Cytomegalovirus (CMV) infection is a frequent and potentially severe event in solid organ transplant (SOT) recipients. Most of available treatment display adverse effects that limit their use.
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Age ≥ 18 years.
- Solid organ transplant recipient (heart, kidney, liver and lung)
- Detectable CMV viral load between 1,000 and 15,000 IU/mL (including 2 borderline values):
- Asymptomatic (no fever or organ dysfunction) ;
- Occurrence within 2 years of transplantation in the absence of primary post-transplant anti-CMV prophylaxis;
You likely can't join if
- Presence of anti-Herpesviridae treatment when CMV replication is detected ([val]aciclovir, [val]ganciclovir, foscarnet, cidofovir, letermovir...
- Pregnant or breast-feeding women.
- Persons under guardianship or trusteeship.
- people under administrative or judicial supervision.
- Subject unable to be contacted in case of emergency.
See the full eligibility criteria
- Age ≥ 18 years.
- Solid organ transplant recipient (heart, kidney, liver and lung)
- Detectable CMV viral load between 1,000 and 15,000 IU/mL (including 2 borderline values):
- Asymptomatic (no fever or organ dysfunction) ;
- Occurrence within 2 years of transplantation in the absence of primary post-transplant anti-CMV prophylaxis;
- Or within 2 years of discontinuation of primary post-transplant anti-CMV prophylaxis if such prophylaxis was used.
- Having signed an informed consent form.
- Affiliated to a social security scheme.
- Presence of anti-Herpesviridae treatment when CMV replication is detected ([val]aciclovir, [val]ganciclovir, foscarnet, cidofovir, letermovir, maribavir, anti-CMV immunoglobulins, cidofovir, brincidofovir).
- Pregnant or breast-feeding women.
- Persons under guardianship or trusteeship.
- people under administrative or judicial supervision.
- Subject unable to be contacted in case of emergency.
The study team makes the final eligibility decision.
Where it's taking place
- Grenoble, Maryland, France
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Grenoble, Maryland, France. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.